EMA has posted its intent to review the safety of JAK inhibitors used to treat several chronic inflammatory disorders (RA, PsA, JIA, AS, UC, atopic dermatitis) based on the release of the Pfizer tofacitinib A3921133 study https://t.co/loG7zWBWHs